Beranda › Kanker Endometrium › North Carolina › Durham
Uji klinis Kanker Endometrium di Durham, NC
16 studi untuk Kanker Endometrium mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Menerima pesertaFase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Menerima pesertaFase 2
- Duke University Medical Center, Durham
A Study of PHST001 in Advanced Solid Tumors
Menerima pesertaFase 1
- Duke Cancer Institute, Durham
Tirzepatide in Obesity-Driven Endometrial Cancer
Menerima pesertaFase awal 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Duke University, Durham
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Menerima pesertaFase 2
- Duke University Medical Center, Durham
DESTINY-PANTUMOUR04
Menerima pesertaStudi observasional
- Research Site, Durham
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Menerima pesertaFase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Menerima pesertaFase 3
- Duke Cancer Institute ( Site 6049), Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Menerima pesertaStudi observasional
- UNC- Chapel Hill, Chapel Hill · 10 mi jauhnya
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Menerima pesertaFase 3
- Duke Cancer Institute, Durham
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Menerima pesertaFase 1
- Duke Cancer Institute, Durham
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Duke University, Durham
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Menerima pesertaFase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Multimedia Aid for Genetic Testing in Gynecologic Oncology
Menerima peserta
- Univeristy of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi jauhnya
Uji klinis Kanker Endometrium di kota lain
- Houston, TX68 studi
- New York City, NY52 studi
- Boston, MA50 studi
- Arlington, VA39 studi
- Nashville, TN38 studi
- Los Angeles, CA34 studi
- St. Louis, MO29 studi
- Philadelphia, PA28 studi
- San Antonio, TX27 studi
- Columbus, OH25 studi
- Oklahoma City, OK25 studi
- Chicago, IL25 studi
Studi lain di Durham
- Kanker Payudara64 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Leukemia Mieloid Akut33 studi
- Kanker Metastatik33 studi
- Kanker Prostat32 studi
- Kanker Paru32 studi
- Kanker Kolorektal28 studi
- Kanker Ovarium27 studi
- Leukemia Limfositik Kronis27 studi
- Gagal Jantung26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.